Events & Webinars

BNMS 2024

In the PSMA era, is there still a place for Xofigo▼ (radium-223 dichloride) in the management of advanced prostate cancer?

An on demand video of the Bayer-sponsored symposium at the British Nuclear Medicine Society (BNMS) Spring Meeting 2024, which took place in Belfast on the 15^th May 2024. In this session Professor Joe O'Sullivan, Clinical Oncologist, Northern Ireland Cancer Centre articulates the potential impact of radionuclide therapies on managing prostate cancer, with a specific focus on radium-223.

This symposium was organised and funded by Bayer.

Xofigo▼ Prescribing Information

NUBEQA^® (darolutamide) Prescribing Information

Speakers

Professor Joe O'Sullivan
Professor Joe O'Sullivan
Professor Joe O'Sullivan, a distinguished oncologist specialising in prostate cancer, holds the position of Professor of Radiation Oncology at Queen's University Belfast. His fervor lies in the care of prostate cancer patients, and he is deeply motivated to enhance outcomes across all facets of this illness while actively pioneering novel therapeutic approaches, particularly within the domains of External Beam Radiation Therapy and Bone-seeking radionuclide therapy.

Evolving mCRPC treatment landscape in 2023

Xofigo®▼ (radium-223 dichloride)

Xofigo Prescribing Information

PP-XOF-GB-0505, February2024

Abbreviations: PSMA; prostate-specific membrane antigen

PP-XOF-GB-0598 | January 2025